enGene LEGEND Trial Update - ENGENE THERAPEUTICS INC

Explicit Guidance:

• BLA Submission: Plans to initiate a Biologics License Application (BLA) for Detalimogene (referred to as "dental imaging" in transcript) before year-end.
• Approval Timeline: Expects potential regulatory approval for Detalimogene in 2027.
• Clinical Data Release: Anticipates providing initial clinical data from the surfactant bladder rinse cohort in mid-2027.
• Field Force Growth: Plans to scale the sales organization to approximately 40–60 representatives over the next year as approval nears.
• Sales Potential: Estimates a potential $1 billion in net sales if capturing 10% of the addressable population (approx. 2,000 patients).

Business-Segment Outlook:

• Market Expansion: Projects significant growth in the high-risk NMIBC market driven by the adoption of bladder-sparing therapies and expanded treatable population.
• Care Setting Focus: Targets 75% of BCG-unresponsive NMIBC patients treated in community practice settings; anticipates broad adoption in this segment due to logistical advantages (no BSL-2 requirements, standard storage).
• Competitive Positioning: Aims to be the first and only non-viral plasmid gene therapy for NMIBC, positioning as a differentiated "sequencing" option alongside viral and non-viral competitors.
• Pipeline Development: Developing a short surfactant bladder rinse (polydocanol) to be added to the regimen; expects this to form a Supplemental BLA (sBLA) to potentially improve efficacy, durability, and reduce dwell time to 30 minutes.

Market and Competitive Outlook:

• Treatment Landscape: Anticipates a shift from "winner-take-all" dynamics to a market where patients sequence through multiple bladder-sparing therapies based on shared decision-making.
• Payer Dynamics: Payer research indicates willingness to cover therapies at parity (assuming NCCN 2A guideline inclusion) even with increased price points; expects favorable pricing dynamics.
• Pricing Reference: Acknowledges that recently approved products in the space range between $500,000 and $700,000 annually, though no formal pricing guidance is provided.
• Adoption Barriers: Notes that ~30% of community practices struggle with viral/novel therapies due to logistical/financial burdens, while ~10% are eager for positive net cost recovery options.

Macro / Industry Outlook:

• Regulatory Environment: Confirmed eligibility by the FDA for BLA submission; alignment reached on statistical analysis plans and efficacy-evaluable population definitions.
• Reimbursement Risks: Monitoring potential impacts of CMS rules (e.g., 340B hospital reimbursement reductions) but believes efficacy and unique value pillars will support reimbursement negotiations.
• Patient Preference: Strong patient preference for bladder preservation drives the need for alternative therapies when radical cystectomy is declined or ineligible.

Strategic Initiatives:

• Commercialization Prep: Activating Medical Science Liaisons (MSLs) for scientific engagement and education; characterizing key accounts to refine field force strategy.
• Product Improvements: Investigating the addition of a surfactant bladder rinse to reduce dwell time and improve throughput, potentially addressing current dwell time limitations.
• Key Personnel: Appointed Dr. Alec Goluboff as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer to support commercialization and growth.
• Lifecycle Management: Preparing for an sBLA submission for the surfactant combination in 2027 following data collection.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Final approval is contingent upon the FDA's review of the BLA package; no specific efficacy "bar" is guaranteed, though the current dataset is deemed sufficient for filing.
• Data Maturity: Durability metrics (12-month CR and duration of response) are still maturing and could evolve; Kaplan-Meier estimates may overestimate final effects.
• Reimbursement Volatility: Potential changes in CMS reimbursement rules (e.g., ASP minus 28% for 340B) could impact market dynamics.
• Competitive Sequencing: Treatment selection is nuanced and depends on individual patient phenotype, prior therapy, and tolerability; no guarantee of market share capture against established viral and chemotherapy options.
• Biomarker Variability: Future biomarker analyses (e.g., urine IL-12) could reveal variability in patient response that impacts targeting strategies.

Management Tone on the Future:

• Confidence Level: High confidence in the regulatory path ("strong feedback" from FDA) and commercial potential due to unique non-viral profile.
• Strategic Outlook: Optimistic about "redefining care" in community settings; views the market as expanding rather than zero-sum.
• Caveats: Management repeatedly emphasizes that treatment selection is not "one-size-fits-all" and depends heavily on shared decision-making between patients and urologists.
• Forward Momentum: Tone is proactive, focusing on "pre-commercial" groundwork and the immediate execution of the BLA filing.

Miscellaneous:

• Terminology Note: The transcript consistently refers to the drug as "Detalimogene," "Detalimagine," "Dettilimogene," "Datalimogene," or "dental imaging." Context confirms this refers to the lead asset (Adalimogene/Detalimogene), a plasmid-based non-viral gene therapy.
• Addressable Population: Estimated at approximately 20,000 patients in the high-risk BCG-unresponsive setting.
• Treatment Burden: Highlights the unique advantage of Detalimogene in requiring no special equipment, no post-treatment urine bleaching precautions, and standard freezer storage, contrasting with competitors requiring BSL-2 handling or bleach protocols.